CN Patent
CN116789643B — 一种2-氨基嘧啶类化合物及其制备方法和应用
Assigned to Hainan Medical College · Expires 2025-05-06 · 1y expired
What this patent protects
本发明公开了一种2‑氨基嘧啶类化合物,其结构式如下: 该化合物可显著抑制胶质母细胞瘤细胞的增殖和迁移,诱导细胞晚期凋亡,促进肿瘤细胞的坏死,并使细胞周期阻滞在G2/M期,可靶向CDK4/6抑制Rb的磷酸化,从而抑制CDK4和CDK6的活性,在制备胶质母细胞瘤治疗药物中具有潜在的应用前景。
USPTO Abstract
本发明公开了一种2‑氨基嘧啶类化合物,其结构式如下: 该化合物可显著抑制胶质母细胞瘤细胞的增殖和迁移,诱导细胞晚期凋亡,促进肿瘤细胞的坏死,并使细胞周期阻滞在G2/M期,可靶向CDK4/6抑制Rb的磷酸化,从而抑制CDK4和CDK6的活性,在制备胶质母细胞瘤治疗药物中具有潜在的应用前景。
Drugs covered by this patent
- Verzenio (abemaciclib) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.